Cosmos Health Inc. reported a net loss of $19.1 million for the fiscal year ending December 31, 2025, on revenues of $65.3 million, marking a 19.9% increase in revenue from $54.4 million in 2024. The company's cost of goods sold rose to $57.4 million, resulting in a gross profit of $7.9 million, which represents an 83.1% increase compared to the previous year. The gross margin improved to 12.1% from 7.9% in 2024, attributed to a favorable shift in the revenue mix towards higher-margin pharmaceutical manufacturing and branded nutraceutical sales.
The company experienced significant operational changes, including nearly doubling revenues from its pharmaceutical manufacturing subsidiary, CANA S.A., which grew from approximately $865,000 to $1.7 million. Additionally, the UK subsidiary, Decahedron Ltd., saw revenue increase from $815,000 to $2.6 million, driven by expanded sales of branded nutraceutical products on Amazon and pharmaceutical products in Greece. The overall revenue growth was supported by an expanded customer base and new distribution channels.
In terms of strategic developments, Cosmos Health has been actively pursuing acquisitions and partnerships to enhance its product offerings and market reach. The company completed the acquisition of Cloudscreen, an AI-driven drug repurposing platform, for $637,080, and has plans to expand its distribution network, particularly in the UAE and other regions. The company also reported a total employee headcount of 163 as of December 31, 2025, reflecting its commitment to building a skilled workforce to support its growth initiatives.
Despite the revenue growth, the company faced challenges, including a substantial increase in general and administrative expenses, which rose by 33.1% to $15.6 million, largely due to provisions for doubtful accounts and increased stock-based compensation. The company recorded a full allowance of $3.9 million against a loan receivable from Doc Pharma, a related party, reflecting concerns over collectability. Looking ahead, Cosmos Health aims to stabilize its growth through strategic expansions and product innovations while managing its operational costs and improving cash flow. The company remains focused on leveraging its existing capabilities to navigate the competitive landscape of the healthcare sector.
About Cosmos Health Inc.
Cosmos Health Inc. is a diversified global healthcare company specializing in the development, manufacturing, and distribution of pharmaceutical and nutraceutical products. Its core segments include generic medicines, innovative drugs, nutraceuticals, biocides, medical devices, and telehealth services. The company leverages proprietary brands, research & development, and strategic partnerships to serve markets across Europe and beyond, emphasizing innovation, cost-efficiency, and a vertically integrated business model.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.